On this page of StockholderLetter.com we present the latest annual shareholder letter from REGENERON PHARMACEUTICALS, INC. — ticker symbol REGN. Reading current and past REGN letters to shareholders can bring important insights into the investment thesis.
ANNUAL REPORT 2023
REGENERON BY THE NUMBERS 12 ~35 6 ~50 1M+ eligible patients received support from our patient support programs in 2023 ~2.3M exomes sequenced by Regeneron Genetics Center since its founding 13.4K+ 23K+ ~2.4M medicines approved in the United States and/or other countries countries with clinical trials Regeneron colleagues worldwide at year end product candidates in clinical development hours of employee community service through our annual Day for Doing Good in 2023 genetics medicines programs in the clinic students supported by Regeneron STEM initiatives since 2020
FORM 10-K
 • shareholder letter icon 4/25/2024 Letter Continued (Full PDF)
 • stockholder letter icon 4/21/2023 REGN Stockholder Letter
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon REGN Benford's Law Stock Score = 99


REGN Shareholder/Stockholder Letter Transcript:

ANNUAL REPORT
2023

REGENERON BY THE NUMBERS
12
~35
6
~50
1M+
eligible patients
received support from
our patient support
programs in 2023
~2.3M
exomes sequenced by
Regeneron Genetics
Center   since its
founding
13.4K+
23K+
~2.4M
medicines approved in
the United States and/or
other countries
countries with clinical
trials
Regeneron colleagues
worldwide at year end
product candidates in
clinical development
hours of employee
community service through
our annual Day for Doing
Good in 2023
genetics medicines
programs in the clinic
students supported
by Regeneron STEM
initiatives since 2020

FORM 10-K



shareholder letter icon 4/25/2024 Letter Continued (Full PDF)
 

REGN Stockholder/Shareholder Letter (REGENERON PHARMACEUTICALS, INC.) | www.StockholderLetter.com
Copyright © 2023 - 2025, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.